An Improved Benefit-Risk Profile of Duvelisib in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Received ≥2 Prior Therapies

Subjects

Subjects :

Oncology
Cancer Research
medicine.medical_specialty
Hematology
business.industry
Chronic lymphocytic leukemia
medicine.disease
Risk profile
Duvelisib
Lymphocytic lymphoma
chemistry.chemical_compound
chemistry
Internal medicine
Medicine
In patient
Progression-free survival
business

Details

ISSN :

21522650

Volume :

19

Database :

OpenAIRE

Journal :

Clinical Lymphoma Myeloma and Leukemia

Accession number :

edsair.doi...........920011c2afcdc12aaf1df05417563954

Full Text :

https://doi.org/10.1016/j.clml.2019.07.209